CD4 and non-Hodgkin lymphoma: In a phase 1 study of CD19-specific BiTE (blinatumomab) in non-Hodgkin lymphoma patients, an analysis of T cell subpopulations indicated that the expansion of T cells induced by blinatumomab was primarily due to the subset of CD4+ and CD8+ effector T cells, and not to naïve or central memory T cells13.